Carmen Jimenez Antunez
Carmen graduated in Pharmaceutical Sciences at the University of Salamanca, and completed her MSc in Drug Research, Development, and Control at the University of Barcelona. During this time, she acquired Biochemical and Medicinal Chemistry experience through a 6-months internship at the University of Montpellier 1 (France) under the supervision of Professor Pierre Cuq, and through a one year research project at the University of Salamanca that culminated with the “Grado de Salamanca” award for her research in Medicinal Chemistry.
In 2017 she obtained her PhD at the University of Cardiff for her work on the “Design, synthesis, and biological evaluation of nucleoside phosphoramidates with potential anticancer activity” under the supervision of Professor Christopher McGuigan and Professor Andrea Brancale, and in collaboration with the pharmaceutical company NuCana BioMed.
In 2018 she joined Professor Paul Brennan’s group as a postdoctoral Scientist. She currently works as part of the SGC Oxford in a multidisciplinary project for the development of target enabling packages facilitating drug development for Alzheimer Research.
Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins
Jiménez C. et al, (2015), European Journal of Medicinal Chemistry, 100, 210 - 222
PROTIDES AS A NEW ANTI-CANCER DRUG FAMILY
McGuigan C. et al, (2015), ANTICANCER RESEARCH, 35, 4312 - 4312